SUN-LB66 Oral Risedronate Treatment in Children With Osteogenesis Imperfecta

J Endocr Soc · 2020 · PMC7208369

Europe PMC

hedged sentences

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Conclusion: Based on our experience, oral risedronate effectively decreased bone resorption, showed a trend towards decrease in fracture rate with improvement in symptoms, and was well tolerated in children with OI.

also in 53,322 other papers

did not reach statistical significanceno p-value reported

There was a clinically significant reduction in the rate of fractures from baseline 0.6 per y (0.4, 0.8) to 0.24 (0, 0.5) by the end of the treatment period, though it did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.